{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:23Z","timestamp":1793018123888,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Persistent pain remains a major unmet need in rheumatoid arthritis (RA), even in patients with adequately controlled inflammatory disease. Cannabinoids have been proposed as potential modulators of pain and inflammation, but their clinical role in RA remains uncertain. To map and critically appraise the available clinical evidence on cannabinoid-related interventions or exposures for pain management in adults with RA. PubMed\/MEDLINE, Scopus, the Directory of Open Access Journals, and the Cochrane Central Register of Controlled Trials were searched for studies published from January 1, 1990, to September 10, 2026. Randomized controlled trials and observational studies evaluating cannabinoid-related interventions or exposures in adults with confirmed RA and reporting pain-related outcomes were eligible. Risk of bias was assessed using Cochrane RoB 2 for randomized trials and ROBINS-I for observational studies. Of 593 records identified, three studies met the eligibility criteria: one randomized placebo-controlled trial and two observational studies. In the randomized trial of 58 patients, nabiximols reduced pain on movement by 0.95 points (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.044), pain at rest by 1.04 points (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.018), and improved sleep quality by 1.17 points (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.027); DAS28 decreased by 0.76 points (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002), while no serious adverse events were reported. Observational studies suggested possible symptomatic benefit but were limited by heterogeneous cannabinoid exposure and serious to critical risk of bias. Current clinical evidence remains insufficient to establish the efficacy or long-term safety of cannabinoids for RA-related pain. Larger, rigorously designed trials using standardized cannabinoid formulations and pain-relevant outcomes are needed.\n                  <\/jats:p>","DOI":"10.1007\/s00296-026-06314-x","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:24:00Z","timestamp":1791188640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9528-0583","authenticated-orcid":false,"given":"Nikolaos","family":"Zintziovas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-5077","authenticated-orcid":false,"given":"Agathi","family":"Karakosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":false,"given":"Paraskevi","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-2894","authenticated-orcid":false,"given":"Georgios","family":"Stefanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-9442","authenticated-orcid":false,"given":"Eleni","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-2859","authenticated-orcid":false,"given":"Petros","family":"Tzimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-6647","authenticated-orcid":false,"given":"Georgia","family":"Micha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"6314_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.31138\/mjr.20230801.oo","volume":"34","author":"M Jahid","year":"2023","unstructured":"Jahid M, Khan KU, Rehan-Ul-Haq, Ahmed RS (2023) Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease. Mediterr J Rheumatol 34:284. https:\/\/doi.org\/10.31138\/mjr.20230801.oo","journal-title":"Mediterr J Rheumatol"},{"key":"6314_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2217\/pmt.16.4","volume":"6","author":"DB Bas","year":"2016","unstructured":"Bas DB, Su J, Wigerblad G, Svensson CI (2016) Pain in Rheumatoid Arthritis: Models and Mechanisms. Pain Manag 6:265\u2013284. https:\/\/doi.org\/10.2217\/pmt.16.4","journal-title":"Pain Manag"},{"key":"6314_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/2076328","volume":"2020","author":"Y Cao","year":"2020","unstructured":"Cao Y, Fan D, Yin Y (2020) Pain Mechanism in Rheumatoid Arthritis: From Cytokines to Central Sensitization. Mediators Inflamm 2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/2076328","journal-title":"Mediators Inflamm"},{"key":"6314_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40674-019-00125-x","volume":"5","author":"L Meert","year":"2019","unstructured":"Meert L, Smeets RJEM, Baert I et al (2019) Treatment of Central Sensitization in Patients With Rheumatoid Arthritis: a Narrative Overview. Curr Treatm Opt Rheumatol 5:179\u2013189. https:\/\/doi.org\/10.1007\/s40674-019-00125-x","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"6314_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11926-016-0581-0","volume":"18","author":"SD Boyden","year":"2016","unstructured":"Boyden SD, Hossain IN, Wohlfahrt A, Lee YC (2016) Non-inflammatory Causes of Pain in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep 18:30. https:\/\/doi.org\/10.1007\/s11926-016-0581-0","journal-title":"Curr Rheumatol Rep"},{"key":"6314_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.14744\/nci.2023.81231","volume":"11","author":"N Mesci","year":"2024","unstructured":"Mesci N, Mesci E, Kandemir EU et al (2024) Impact of central sensitization on clinical parameters in patients with rheumatoid arthritis. North Clin Istanb 11:140\u2013146. https:\/\/doi.org\/10.14744\/nci.2023.81231","journal-title":"North Clin Istanb"},{"key":"6314_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/ph16020148","volume":"16","author":"B Rezende","year":"2023","unstructured":"Rezende B, Alencar AKN, de Bem GF et al (2023) Endocannabinoid System: Chemical Characteristics and Biological Activity. Pharmaceuticals 16:148. https:\/\/doi.org\/10.3390\/ph16020148","journal-title":"Pharmaceuticals"},{"key":"6314_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00482-015-0084-3","volume":"30","author":"M-A Fitzcharles","year":"2016","unstructured":"Fitzcharles M-A, Baerwald C, Ablin J, H\u00e4user W (2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz 30:47\u201361. https:\/\/doi.org\/10.1007\/s00482-015-0084-3","journal-title":"Der Schmerz"},{"key":"6314_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524","journal-title":"Ann Rheum Dis"},{"key":"6314_CR10","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1002\/mco2.509","volume":"5","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang Y, Liu X (2024) Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm (Beijing) 5:e509. https:\/\/doi.org\/10.1002\/mco2.509","journal-title":"MedComm (Beijing)"},{"key":"6314_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-025-01184-x","volume":"27","author":"P Pham","year":"2025","unstructured":"Pham P, Lee YC (2025) Non-Pharmacological Pain Management of Rheumatoid Arthritis. Curr Rheumatol Rep 27:21. https:\/\/doi.org\/10.1007\/s11926-025-01184-x","journal-title":"Curr Rheumatol Rep"},{"key":"6314_CR12","doi-asserted-by":"publisher","first-page":"991677","DOI":"10.3389\/fmed.2022.991677","volume":"9","author":"J Majnik","year":"2022","unstructured":"Majnik J, Cs\u00e1sz\u00e1r-Nagy N, B\u00f6cskei G et al (2022) Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis. Front Med (Lausanne) 9:991677. https:\/\/doi.org\/10.3389\/fmed.2022.991677","journal-title":"Front Med (Lausanne)"},{"key":"6314_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","volume":"16","author":"A Zhang","year":"2018","unstructured":"Zhang A, Lee YC (2018) Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep 16:603\u2013610. https:\/\/doi.org\/10.1007\/s11914-018-0473-5","journal-title":"Curr Osteoporos Rep"},{"key":"6314_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jbspin.2004.01.010","volume":"72","author":"A Coutaux","year":"2005","unstructured":"Coutaux A, Adam F, Willer J-C, Le Bars D (2005) Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 72:359\u2013371. https:\/\/doi.org\/10.1016\/j.jbspin.2004.01.010","journal-title":"Joint Bone Spine"},{"key":"6314_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s13075-014-0470-8","volume":"16","author":"H-G Schaible","year":"2014","unstructured":"Schaible H-G (2014) Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther 16:470. https:\/\/doi.org\/10.1186\/s13075-014-0470-8","journal-title":"Arthritis Res Ther"},{"key":"6314_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/biof.1168","volume":"40","author":"L Cristino","year":"2014","unstructured":"Cristino L, Becker T, Di Marzo V (2014) Endocannabinoids and energy homeostasis: An update. BioFactors 40:389\u2013397. https:\/\/doi.org\/10.1002\/biof.1168","journal-title":"BioFactors"},{"key":"6314_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpsc.2020.07.016","volume":"6","author":"H-C Lu","year":"2021","unstructured":"Lu H-C, Mackie K (2021) Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging 6:607\u2013615. https:\/\/doi.org\/10.1016\/j.bpsc.2020.07.016","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"6314_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"AC Howlett","year":"2002","unstructured":"Howlett AC, Barth F, Bonner TI et al (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54:161\u2013202. https:\/\/doi.org\/10.1124\/pr.54.2.161","journal-title":"Pharmacol Rev"},{"key":"6314_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41398-020-0832-8","volume":"10","author":"R Tao","year":"2020","unstructured":"Tao R, Li C, Jaffe AE et al (2020) Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry 10:158. https:\/\/doi.org\/10.1038\/s41398-020-0832-8","journal-title":"Transl Psychiatry"},{"key":"6314_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","volume":"10","author":"DA Kendall","year":"2017","unstructured":"Kendall DA, Yudowski GA (2017) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front Cell Neurosci 10:294. https:\/\/doi.org\/10.3389\/fncel.2016.00294","journal-title":"Front Cell Neurosci"},{"key":"6314_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-319-20825-1_6","volume":"231","author":"GA Cabral","year":"2015","unstructured":"Cabral GA, Ferreira GA, Jamerson MJ (2015) Endocannabinoids and the immune system in health and disease. Handb Exp Pharmacol 231:185\u2013211. https:\/\/doi.org\/10.1007\/978-3-319-20825-1_6","journal-title":"Handb Exp Pharmacol"},{"key":"6314_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Gali\u00e8gue","year":"1995","unstructured":"Gali\u00e8gue S, Mary S, Marchand J et al (1995) Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur J Biochem 232:54\u201361. https:\/\/doi.org\/10.1111\/j.1432-1033.1995.tb20780.x","journal-title":"Eur J Biochem"},{"issue":"Suppl","key":"6314_CR23","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1007\/BF02562332","volume":"34","author":"V Di Marzo","year":"1999","unstructured":"Di Marzo V, De Petrocellis L, Bisogno T, Melck D (1999) Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids 34(Suppl):S319\u2013S325. https:\/\/doi.org\/10.1007\/BF02562332","journal-title":"Lipids"},{"key":"6314_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fnmol.2020.00132","volume":"13","author":"C Piette","year":"2020","unstructured":"Piette C, Cui Y, Gervasi N, Venance L (2020) Lights on endocannabinoid-mediated synaptic potentiation. Front Mol Neurosci 13:132. https:\/\/doi.org\/10.3389\/fnmol.2020.00132","journal-title":"Front Mol Neurosci"},{"key":"6314_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"H-C Lu","year":"2016","unstructured":"Lu H-C, Mackie K (2016) An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 79:516\u2013525. https:\/\/doi.org\/10.1016\/j.biopsych.2015.07.028","journal-title":"Biol Psychiatry"},{"key":"6314_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/physrev.00019.2008","volume":"89","author":"M Kano","year":"2009","unstructured":"Kano M, Ohno-Shosaku T, Hashimotodani Y et al (2009) Endocannabinoid-Mediated Control of Synaptic Transmission. Physiol Rev 89:309\u2013380. https:\/\/doi.org\/10.1152\/physrev.00019.2008","journal-title":"Physiol Rev"},{"key":"6314_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.neuron.2004.08.036","volume":"43","author":"V Chevaleyre","year":"2004","unstructured":"Chevaleyre V, Castillo PE (2004) Endocannabinoid-Mediated Metaplasticity in the Hippocampus. Neuron 43:871\u2013881. https:\/\/doi.org\/10.1016\/j.neuron.2004.08.036","journal-title":"Neuron"},{"key":"6314_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nn832","volume":"5","author":"GL Gerdeman","year":"2002","unstructured":"Gerdeman GL, Ronesi J, Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446\u2013451. https:\/\/doi.org\/10.1038\/nn832","journal-title":"Nat Neurosci"},{"key":"6314_CR29","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1073\/pnas.122149199","volume":"99","author":"D Robbe","year":"2002","unstructured":"Robbe D, Kopf M, Remaury A et al (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 99:8384\u20138388. https:\/\/doi.org\/10.1073\/pnas.122149199","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6314_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","volume":"369","author":"B Costa","year":"2004","unstructured":"Costa B, Colleoni M, Conti S et al (2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369:294\u2013299. https:\/\/doi.org\/10.1007\/s00210-004-0871-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"6314_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0304-3940(96)13308-5","volume":"221","author":"U Herzberg","year":"1997","unstructured":"Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997) The analgesic effects of R(+)-WIN 55,212\u20132 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221:157\u2013160. https:\/\/doi.org\/10.1016\/S0304-3940(96)13308-5","journal-title":"Neurosci Lett"},{"key":"6314_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1523\/JNEUROSCI.1945-17.2017","volume":"38","author":"PP Klinger-Gratz","year":"2018","unstructured":"Klinger-Gratz PP, Ralvenius WT, Neumann E et al (2018) Acetaminophen relieves inflammatory pain through CB1 cannabinoid receptors in the rostral ventromedial medulla. J Neurosci 38:322\u2013334. https:\/\/doi.org\/10.1523\/JNEUROSCI.1945-17.2017","journal-title":"J Neurosci"},{"key":"6314_CR33","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","volume":"97","author":"AM Malfait","year":"2000","unstructured":"Malfait AM, Gallily R, Sumariwalla PF et al (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97:9561\u20139566. https:\/\/doi.org\/10.1073\/pnas.160105897","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6314_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1124\/mol.63.2.429","volume":"63","author":"R Sancho","year":"2003","unstructured":"Sancho R, Calzado MA, Di Marzo V et al (2003) Anandamide Inhibits Nuclear Factor-\u03baB Activation through a Cannabinoid Receptor-Independent Pathway. Mol Pharmacol 63:429\u2013438. https:\/\/doi.org\/10.1124\/mol.63.2.429","journal-title":"Mol Pharmacol"},{"key":"6314_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1874467212666190215112036","volume":"12","author":"L Ye","year":"2019","unstructured":"Ye L, Cao Z, Wang W, Zhou N (2019) New Insights in Cannabinoid Receptor Structure and Signaling. Curr Mol Pharmacol 12:239\u2013248. https:\/\/doi.org\/10.2174\/1874467212666190215112036","journal-title":"Curr Mol Pharmacol"},{"key":"6314_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","volume":"11","author":"C Muller","year":"2019","unstructured":"Muller C, Morales P, Reggio PH (2019) Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 11:487. https:\/\/doi.org\/10.3389\/fnmol.2018.00487","journal-title":"Front Mol Neurosci"},{"key":"6314_CR37","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","volume":"285","author":"E Kozela","year":"2010","unstructured":"Kozela E, Pietr M, Juknat A et al (2010) Cannabinoids \u22069-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-\u03baB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285:1616\u20131626. https:\/\/doi.org\/10.1074\/jbc.M109.069294","journal-title":"J Biol Chem"},{"key":"6314_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5152\/eurjrheum.2017.17025","volume":"4","author":"N Barrie","year":"2019","unstructured":"Barrie N, Manolios N (2019) The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. Eur J Rheumatol 4:210\u2013218. https:\/\/doi.org\/10.5152\/eurjrheum.2017.17025","journal-title":"Eur J Rheumatol"},{"key":"6314_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"6314_CR40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"6314_CR41","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"6314_CR42","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"6314_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","volume":"45","author":"DR Blake","year":"2006","unstructured":"Blake DR, Robson P, Ho M et al (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:50\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/kei183","journal-title":"Rheumatology"},{"key":"6314_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s42238-022-00154-9","volume":"4","author":"N Frane","year":"2022","unstructured":"Frane N, Stapleton E, Iturriaga C et al (2022) Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. J Cannabis Res 4:47. https:\/\/doi.org\/10.1186\/s42238-022-00154-9","journal-title":"J Cannabis Res"},{"key":"6314_CR45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/08998280.2025.2473863","volume":"38","author":"K Shrestha","year":"2025","unstructured":"Shrestha K, Subedi P, Regmi A et al (2025) Inpatient outcomes of rheumatoid arthritis in hospitalized patients using cannabis: data from the National Inpatient Sample. Proc (Bayl Univ Med Cent) 38:259\u2013264. https:\/\/doi.org\/10.1080\/08998280.2025.2473863","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"1","key":"6314_CR46","doi-asserted-by":"publisher","first-page":"CD008921","DOI":"10.1002\/14651858.CD008921.pub2","volume":"2012","author":"BL Richards","year":"2012","unstructured":"Richards BL, Whittle SL, Buchbinder R (2012) Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012(1):CD008921. https:\/\/doi.org\/10.1002\/14651858.CD008921.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6314_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00482-015-0084-3","volume":"30","author":"M-A Fitzcharles","year":"2016","unstructured":"Fitzcharles M-A, Baerwald C, Ablin J, H\u00e4user W (2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz 30:47\u201361. https:\/\/doi.org\/10.1007\/s00482-015-0084-3","journal-title":"Der Schmerz"},{"key":"6314_CR48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/acr.22727","volume":"68","author":"M Fitzcharles","year":"2016","unstructured":"Fitzcharles M, Ste-Marie PA, H\u00e4user W et al (2016) Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken) 68:681\u2013688. https:\/\/doi.org\/10.1002\/acr.22727","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6314_CR49","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1097\/RHU.0000000000001745","volume":"28","author":"C Schulze-Schiappacasse","year":"2022","unstructured":"Schulze-Schiappacasse C, Dur\u00e1n J, Bravo-Jeria R et al (2022) Are cannabis, cannabis-derived products, and synthetic cannabinoids a therapeutic tool for rheumatoid arthritis? A friendly summary of the body of evidence. J Clin Rheumatol 28:e563\u2013e567. https:\/\/doi.org\/10.1097\/RHU.0000000000001745","journal-title":"J Clin Rheumatol"},{"key":"6314_CR50","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/rheumatology\/ker119","volume":"50","author":"GJ Macfarlane","year":"2011","unstructured":"Macfarlane GJ, El-Metwally A, De Silva V et al (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology 50:1672\u20131683. https:\/\/doi.org\/10.1093\/rheumatology\/ker119","journal-title":"Rheumatology"},{"key":"6314_CR51","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","volume":"159","author":"E Stockings","year":"2018","unstructured":"Stockings E, Campbell G, Hall WD et al (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 159:1932\u20131954. https:\/\/doi.org\/10.1097\/j.pain.0000000000001293","journal-title":"Pain"},{"key":"6314_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.14744\/nci.2023.43669","volume":"11","author":"JF de Carvalho","year":"2024","unstructured":"de Carvalho JF, Ribeiro MFLS, Skare T (2024) Cannabis therapy in rheumatological diseases: a systematic review. North Clin Istanb 11:361\u2013366. https:\/\/doi.org\/10.14744\/nci.2023.43669","journal-title":"North Clin Istanb"},{"key":"6314_CR53","doi-asserted-by":"publisher","first-page":"e0022","DOI":"10.5041\/RMMJ.10509","volume":"14","author":"N Paland","year":"2023","unstructured":"Paland N, Hamza H, Pechkovsky A et al (2023) Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions. Rambam Maimonides Med J 14:e0022. https:\/\/doi.org\/10.5041\/RMMJ.10509","journal-title":"Rambam Maimonides Med J"},{"key":"6314_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00296-026-06105-4","volume":"46","author":"D Fedkov","year":"2026","unstructured":"Fedkov D, Yevstifeiev D, Iaremenko O et al (2026) Baseline pain, fatigue, and sleep quality predict 12-week pain improvement in inflammatory arthritis: retrospective real-world analysis of a digital health application cohort. Rheumatol Int 46:77. https:\/\/doi.org\/10.1007\/s00296-026-06105-4","journal-title":"Rheumatol Int"},{"key":"6314_CR55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-018-4005-5","volume":"38","author":"B Fautrel","year":"2018","unstructured":"Fautrel B, Alten R, Kirkham B et al (2018) Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 38:935\u2013947. https:\/\/doi.org\/10.1007\/s00296-018-4005-5","journal-title":"Rheumatol Int"},{"key":"6314_CR56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R et al (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:685\u2013695. https:\/\/doi.org\/10.1007\/s00296-015-3415-x","journal-title":"Rheumatol Int"},{"key":"6314_CR57","unstructured":"Ranganath V, Cooper Z (2024) Therapeutic response of cannabidiol in rheumatoid arthritis (NCT04911127). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04911127. Accessed 10 Sep 2026"},{"key":"6314_CR58","unstructured":"Incannex Healthcare Ltd (2026) Safety and effect on pain and function according to RAPID-3 of IHL-675A in patients with rheumatoid arthritis (CHAPPII) (NCT05942911). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05942911. Accessed 10 Sep 2026"},{"key":"6314_CR59","unstructured":"Smith CL (2025) Cannabichromene safety in rheumatoid arthritis (NCT07087938). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT07087938. Accessed 10 Sep 2026"},{"key":"6314_CR60","unstructured":"Aston E (2025) Impact of cannabis on pain and inflammation among patients with rheumatoid or psoriatic arthritis (NCT04269993). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04269993. Accessed 10 Sep 2026"},{"key":"6314_CR61","doi-asserted-by":"publisher","unstructured":"Zaskow C (2014) Efficacy of a topical cannabinoid preparation in decreasing symptoms of rheumatoid arthritis (ISRCTN29199098). ISRCTN Registry. https:\/\/doi.org\/10.1186\/ISRCTN29199098. Accessed 10 Sep 2026","DOI":"10.1186\/ISRCTN29199098"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06314-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:27Z","timestamp":1793016387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06314-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6314"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06314-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a scoping review of previously published studies and did not involve any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation, artificial intelligence (AI) assistance (ChatGPT, OpenAI; GPT-5.6) was used from August 1 to September 11, 2026, to assist with language refinement and improvement of the clarity and organization of selected sections of the manuscript. All scientific content, interpretations, and conclusions were critically reviewed, verified, and approved by the authors, who take full responsibility for the final content of the manuscript.","order":3,"name":"Ethics","label":"AI Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"275"}}